Nalmefene Hydrochloride Hydrate

PreclinicalSmall molecule

Nalmefene Hydrochloride Hydrate is one of 50 small molecule programs targeting Alcohol Dependence. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alcohol DependenceActive, not recruiting

Alcohol DependencePreclinical

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Alcohol Dependence

#DrugCompanyPhaseTrials

Revia

Teva

Approved

21 2

Minipress

Pfizer

Approved

3 3

Antabuse

Teva

Approved

1 4

Depacon

AbbVie

Approved

1 5

Topamax

WWim Janssens

Approved

6 6

Selincro

IIndivior Inc.

Approved

5 7

Celexa

Dayvigo

Lopid

Marinol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alcohol Dependence1 trial

Post-Marketing Surveillance Study of Nalmefene Hydrochloride Hydrate in Patients with Alcohol Dependence

Completed· Otsuka logo

Otsuka··NCT04107051·533 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Nalmefene Hydrochloride Hydrate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nalmefene Hydrochloride Hydrate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nalmefene Hydrochloride Hydrate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Otsuka company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Otsuka

Nalmefene Hydrochloride Hydrate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alcohol Dependence1 trial

References

Drug Info

Quick Facts

Related News